2025-523374-17-03RecruitingPhase 4
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Jun 2026
Brief summary (registry, in English)
To determine by means of 18F-FDG PET/CT and 99mTc-Tetrofosmin SPECT whether myocardial IR affects cardiac function and coronary flow and is therefore a risk factor for cardiovascular events and diabetic cardiomyopathy in DM2 patients with myocardial IR phenotype
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 4 Mar 2026
- Start date
- 15 Oct 2026
- Lead sponsor
- Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
- Diseases
- Type 2 diabetes
- EU CT number
- 2025-523374-17-03
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous CVD events
- treatment with SGLT2 inhibitors or GLP-1 analogs.
Other
- hepatic and kidney complications
- claustrophobia to PET/CT and SPECT
Who the study is looking for
- BMI around 30 kg/m2
- DM2
- no-smoking; no-alcohol
- HbA1c between 7-9%
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.